Andere Sprachen Alnylam Pharmaceuticals, Inc.

Aktien

A0CBCK

US02043Q1076

ALNY

Pharmazeutika

Markt geschlossen - Nasdaq Andere Börsenplätze 21:00:00 13.03.2026			% 5 Tage	Veränd. 1. Jan.
313,41 ^USD	-1,20 %		-2,26 %	-21,18 %

05.03.	Tenaya Therapeutics und Alnylam Pharmaceuticals schließen Forschungskooperation	CI
05.03.	Tenaya Therapeutics schließt 1,13-Milliarden-Dollar-Deal mit Alnylam für Herzkrankheits-Therapien ab	RE

Andere Sprachen

10.03.	Alnylam to Webcast TTR Investor Webinar
05.03.	Tenaya Therapeutics and Alnylam Pharmaceuticals Enter Research Collaboration Agreement
05.03.	Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments
05.03.	Tenaya Therapeutics Signs Potential $1.13 Billion Deal With Alnylam
05.03.	Tenaya Therapeutics enters into research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapeutics
05.03.	Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
05.03.	Alnylam Pharmaceuticals Insider Sold Shares Worth $2,227,698, According to a Recent SEC Filing
03.03.	Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
02.03.	Alnylam Pharmaceuticals receives positive recommendation from Canada's drug agency for public reimbursement of Amvuttra
02.03.	Intellia gets FDA nod to resume second gene therapy trial after safety pause
23.02.	Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
18.02.	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,284,980, According to a Recent SEC Filing
18.02.	Alnylam Pharmaceuticals Insider Sold Shares Worth $607,448, According to a Recent SEC Filing
18.02.	Alnylam Pharmaceuticals Insider Sold Shares Worth $2,157,542, According to a Recent SEC Filing
18.02.	Alnylam Pharmaceuticals Insider Sold Shares Worth $695,201, According to a Recent SEC Filing
17.02.	Analyst recommendations: Accenture, Dollar Tree, DraftKings, Moderna, Walmart…
12.02.	Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
12.02.	Alnylam Pharmaceuticals : Q4 2025 Earnings Presentation ›
12.02.	Alnylam Pharmaceuticals Q4 Adjusted Net Income, Revenue Rise; Issues 2026 Outlook
12.02.	Alnylam: Q4 Earnings Snapshot
12.02.	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $1.25 per Share
12.02.	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q4 Revenue $1.10B, vs. FactSet Est of $1.15B
12.02.	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
11.02.	Pharma companies left out of Trump's drug-pricing deals look for way in
29.01.	Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results